Palvella Therapeutics (PI6) AI Stock Analysis

Company Guidance

Palvella expects FDA’s 6-month review goal for QTORIN rapamycin, with a PDUFA target action date of February 28, 2027, and, if approved, a launch in the first half of 27; more than 70% of surveyed physicians said they would prescribe, more than 70% expect to begin prescribing within 3 months of approval, about 70 people will be in the field at launch including approximately 40 frontline sales reps, with the team in place about 2 months ahead of the PDUFA date, and the company expects a broad label covering pediatric and adult use, all severities, and long term administration. Palvella expects more than 30 thousand diagnosed U.S. patients at $100 thousand to $200 thousand per patient per year, reaching $1 billion at peak with modest penetration, anticipates favorable coverage in the orphan pricing corridor, does not anticipate a bolus and expects steady growth quarter over quarter, expects early demand to be strong with revenue realization in line with other first in disease launches, and does not intend to provide specific 2027 revenue guidance. The company remains on track to initiate the Phase 3 cutaneous venous malformations study this quarter, expects to announce the study design at initiation, expects top line results from the Phase II LOTU-2 study in the second half of 27, remains on track to initiate the DSAP Phase 3 study this quarter, and expects existing cash to fund Palvella deep into the commercial launch.